Permethrin, Imidacloprid, Pyriproxyfen

Verify with FDA CVM →

26 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
26
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Permethrin, Imidacloprid, Pyriproxyfen

Administration Routes

Topical

Species Affected

Dog 26

Most Affected Breeds

Crossbred Canine/dog 3
Dog (unknown) 3
Shepherd Dog - German 3
Chihuahua 3
Terrier - Boston 2
Shih Tzu 2
Terrier - Bull - American Pit 2
Retriever - Labrador 2
Pinscher - Miniature 1
Retriever - Golden 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 17
Vomiting 4
Scratching 3
Lethargy (see also Central nervous system depression in Neurological) 3
Lack of efficacy (ectoparasite) - tick NOS 2
Weight loss 2
Lack of efficacy (ectoparasite) - mite NOS 2
Seizure NOS 2
Not eating 2
Hiding 2
Behavioural disorder NOS 2
Lateral recumbency 1

Outcome Breakdown

Outcome Unknown
19 (73.1%)
Ongoing
5 (19.2%)
Recovered/Normal
2 (7.7%)

Data Summary

Metric Value
Total adverse event reports 26
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 1
Distinct breeds in reports 14
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Permethrin, Imidacloprid, Pyriproxyfen Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 26 adverse event reports referencing Permethrin, Imidacloprid, Pyriproxyfen, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Permethrin, Imidacloprid, Pyriproxyfen. Reported administration route is Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Permethrin, Imidacloprid, Pyriproxyfen reports are Dog (26 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (3), Dog (unknown) (3), Shepherd Dog - German (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Permethrin, Imidacloprid, Pyriproxyfen are Lack of efficacy (ectoparasite) - flea (17), Vomiting (4), Scratching (3), Lethargy (see also Central nervous system depression in Neurological) (3). Of the 26 reports with a coded outcome, Outcome Unknown is the leading category at 73.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Permethrin, Imidacloprid, Pyriproxyfen.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial